老百姓(603883.SH):聘任官文提擔任公司副總裁
格隆匯 11 月 13日丨老百姓(603883.SH)公佈,公司於2020年11月13日召開第三屆董事會第三十三次會議,審議通過了《關於聘任高級管理人員的議案》。
根據《公司章程》的有關規定,經公司執行總裁王黎提名,董事會提名、薪酬與考核委員會審查,同意聘任官文提擔任公司副總裁,任期自本次董事會審議通過之日至第三屆董事會任期屆滿。
官文提,1984年出生,中國國籍,無境外永久居留權,本科學歷,EMBA在讀,先後就職於廣州市數華貿易有限公司運營總監,深圳市都市醫藥股份有限公司電商事業部總監,深圳市海王星辰健康藥房連鎖有限公司事業部總經理。現任公司新零售中心總經理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.